Collaboration draws on the full versatility of NMR spectroscopy — dozens of published pulse sequences — paired with Resonate Bio’s algorithms to capture the complete molecular picture drug design demands
Vienna, Austria — 14 July 2026 — Resonate Bio, a Vienna-based biotech applying artificial intelligence and nuclear magnetic resonance (NMR) to drug dynamic proteins, today announced a research collaboration with the University of Vienna. Many of the most important therapeutic targets — transcription factors among them — remain difficult to drug because their dynamics are effectively invisible to conventional approaches. The collaboration builds on Prof. Robert Konrat’s rare command of NMR’s experimental landscape at the University of Vienna, whose lab captures the full molecular detail of how drug candidates bind to proteins in their native state — insights that crystal-based structures often miss.
NMR is an unusually flexible technique, with a versatile toolkit of specialized pulse sequences developed to interrogate the different aspects of molecular interactions. Under the agreement, Resonate Bio will work with Prof. Konrat’s group — drawing on his deep knowledge of that experimental landscape — to advance what Resonate Structures can reveal for a given target. Resonate Structures are the company’s AI-NMR-derived structural ensembles of how drugs bind their disease-causing protein targets. Where conventional structural biology gives static snapshots — photos — this approach generates movies: a direct, in-solution view of dynamic molecular ensembles, revealing dimensions of molecular behavior static structures simply can’t capture.
“Working with Robert’s group gives us access to a breadth of NMR expertise and the experimental capacity to put it into practice, something most companies could never build on their own,” said Dr. Darryl McConnell, Co-Founder and Chief Executive Officer of Resonate Bio. “Being able to draw on the right experiment for a given target means we can tailor our platform to the specific molecular design questions, many of which are out of reach with current methods.”
“Protein-drug complexes aren’t static — our approach doesn’t need to coax them into artificial states like other methods do, we observe them in their native state,” said Prof. Robert Konrat, scientific co-founder of Resonate Bio, whose University of Vienna lab pioneered the underlying techniques. “NMR gives us an unusually rich toolkit to work with, and this collaboration is about putting that breadth to work for Resonate Bio’s targets.”
About Resonate Bio — Resonate Bio combines nuclear magnetic resonance (NMR) spectroscopy and artificial intelligence to generate experimentally grounded structural ensembles of protein–ligand interactions in solution — what the company calls Resonate Structures. Where conventional structural biology gives static snapshots, Resonate Bio makes movies, directly observing dynamic molecular ensembles to unlock targets whose druggability is only visible in motion. The company was founded in Vienna, Austria as a spin-out of the University of Vienna’s Christian Doppler Laboratory.
To learn more, visit https://www.resonate.bio or contact media@resonate.bio
